Naloxone Nasal Spray — Competitive Intelligence Brief

Naloxone Nasal Spray (Naloxone Nasal Spray) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Emergency Medicine / Toxicology.

phase 3 Opioid receptor antagonist Mu opioid receptor (primary); delta and kappa opioid receptors Emergency Medicine / Toxicology Small molecule

Target snapshot

Naloxone Nasal Spray (Naloxone Nasal Spray) — Pocket Naloxone Corp. Naloxone is a competitive opioid receptor antagonist that rapidly blocks opioid effects and reverses opioid overdose.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naloxone Nasal Spray TARGET	Naloxone Nasal Spray	Pocket Naloxone Corp	phase 3	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)
Naltrexone Oral Product	Naltrexone Oral Product	Texas Tech University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
Nalmefene HCl injection	Nalmefene HCl injection	Leiden University Medical Center	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
Naltrexone Pill	Naltrexone Pill	Albert Einstein Healthcare Network	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
naltrexone (Revia)	naltrexone (Revia)	University of North Carolina, Chapel Hill	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class